Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932046 | 0.65 | LDHA (0.31) | LDHA | |
| SCHEMBL290575 | 0.61 | TAAR1 (0.42) | — | |
| SCHEMBL6237482 | 0.61 | — | — | |
| SCHEMBL4998332 | 0.59 | HTR2C (0.50) | — | |
| SCHEMBL9030265 | 0.59 | KDM1A (0.46) | — | |
| SCHEMBL7447299 | 0.59 | — | — | |
| SCHEMBL3389545 | 0.59 | NOS1 (0.46) | — | |
| SCHEMBL6984661 | 0.59 | KDM4E (0.31) | — | |
| SCHEMBL6653603 | 0.58 | GAA (0.45) | — | |
| SCHEMBL7196817 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090311249-A1 | Capecitabine Combination Therapy | ARIAD PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| EP-2032168-A1 | CAPECITABINE COMBINATION THERAPY | ARIAD GENE THERAPEUTICS, INC. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007143212-A1 | CAPECITABINE COMBINATION THERAPY | ARIAD GENE THERAPEUTICS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| US-6710086-B1 | CHEMICALLY MODIFIED PHARMACOLOGICALLY ACTIVE AGENT IN CARRIER; REDUCE THE DAMAGE TO THE GASTROINTESTINAL TRACT | MEDINOX, INC. | 2004-03-23 | — | — | US | disclosed |
| US-6649591-B2 | Dithiocarbamates linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein); treating cerebral stroke and other ischemia/reperfusion injury | MEDINOX, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030181495-A1 | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor | MEDINOX, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6596770-B2 | Disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of)the species that induce the expression of nitric oxide synthase | MEDINOX, INC. | 2003-07-22 | — | — | US | disclosed |
| US-20030087840-A1 | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor | MEDINOX, INC. | 2003-05-08 | — | — | US | disclosed |
| US-20020151540-A1 | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor | MEDINOX, INC. | 2002-10-17 | — | — | US | disclosed |
| US-6407135-B1 | NITRIC OXIDE SCAVENGER COVALENTLY BONDED TO NON-STEROIDAL ANTIINFLAMMATORY AGENT OR OTHER DRUG; SIDE EFFECT REDUCTION | MEDINOX, INC. | 2002-06-18 | — | — | US | disclosed |
| US-6093743-A | FOR IN VIVO REDUCTION OF LEVELS OF NITRIC OXIDE, SUCH AS ARE INDUCED BY A VARIETY OF DISEASE STATES, AND FOR TREATMENT OF INFECTIOUS AND/OR INFLAMMATORY CONDITIONS | MEDINOX INC. (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1001932-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | Medinox, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999066918-A9 | THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR | MEDINOX INC (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1999040907-A1 | METHODS FOR THE CONTROLLED DELIVERY OF CARBON DISULFIDE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999040787-A1 | MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED THERAPEUTIC METHODS EMPLOYING SAME | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0927159-A1 | POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | Medinox, Inc. (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998055453-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0866695-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | Medinox, Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1998011066-A1 | POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | MEDINOX, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1997018805-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS | MEDINOX, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087840-A1 | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor | NOS1, PTGS1, NOS2 | LDHA 845/4885 |
| US-20090311249-A1 | Capecitabine Combination Therapy | RICTOR, MTOR, EIF4E | LDHA 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.